Venetoclax is effective in the clinic as a monotherapy against chronic lymphocytic leukemia (CLL), which expresses BCL-2 at high levels [6], as well as in AML [17] and other hematologic malignancies [42]. The gene discussed is BCL2; the disease is acute myeloid leukemia.